• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.

作者信息

Israel M, Karkowsky A M, Pegg W J

出版信息

Cancer Chemother Pharmacol. 1980;4(2):79-82. doi: 10.1007/BF00254026.

DOI:10.1007/BF00254026
PMID:7389059
Abstract

In connection with pharmacologic studies with AD 32, isotopically-labeled drug prepared from 1-[14C]-trifluoroacetic anhydride and adriamycin-14-valerate was used to determine murine serum and urine levels of radioactivity. Other studies, performed in parallel, measured serum and urinary total fluorescence. Serum fluorescence disappeared in a biphasic pattern, with an initial rapid rate of disappearance followed by a somewhat slower phase. For the first hour, serum radioactivity levels were not significantly different than those measured by fluorescence. After this, however, serum radioactivity decayed at a much slower rate than did fluorescence. Furthermore, a large fraction of the injected radioactivity was found excreted in the urine, whereas urine accounted for only a small fraction of the fluorescence. These results suggest the formation, in part, of a hitherto unrecognized nonfluorescent metabolite, most probably N-trifluoracetyldaunosamine.

摘要

相似文献

1
Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.
Cancer Chemother Pharmacol. 1980;4(2):79-82. doi: 10.1007/BF00254026.
2
Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.
Cancer Chemother Pharmacol. 1981;6(1):25-30. doi: 10.1007/BF00253006.
3
Radioactive species in rat urines and tissues after [14C] AD 32 administration.
Cancer Chemother Pharmacol. 1984;12(3):154-6. doi: 10.1007/BF00256537.
4
Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.
Cancer Res. 1978 Feb;38(2):365-70.
5
Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate.
J Pharmacol Exp Ther. 1978 Mar;204(3):696-701.
6
Possible relevance of N-trifluoroacetyladriamycin (AD 41) in the antitumoral activity of N-trifluoroacetyladriamycin-14-valerate (AD 32) in tumor-bearing mice. I. Pharmacokinetic evidence.N-三氟乙酰阿霉素(AD 41)在荷瘤小鼠体内对N-三氟乙酰阿霉素-14-戊酸酯(AD 32)抗肿瘤活性的可能相关性。I. 药代动力学证据。
Cancer Treat Rep. 1980 Aug-Sep;64(8-9):873-8.
7
Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.
Cancer Res. 1976 Jun;36(6):2108-9.
8
Pharmacology of N-benzyladriamycin-14-valerate in the rat.大鼠中N-苄基阿霉素-14-戊酸酯的药理学
Cancer Chemother Pharmacol. 1999;43(5):419-26. doi: 10.1007/s002800050917.
9
Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.大鼠中N,N-二(正丁基)阿霉素-14-戊酸酯的药理学
Cancer Chemother Pharmacol. 1996;37(5):472-8. doi: 10.1007/s002800050414.
10
Quantitative thin-layer chromatographic measurement of n-trifluoroacetyladriamycin-14-valerate (AD 32) and trifluoroacetyladriamycin (AD 41) in blood and tissues.血液和组织中n-三氟乙酰阿霉素-14-戊酸酯(AD 32)和三氟乙酰阿霉素(AD 41)的定量薄层色谱测定
J Chromatogr. 1979 Jun 11;163(2):195-200. doi: 10.1016/s0378-4347(00)81463-2.

引用本文的文献

1
Valrubicin.缬柔比星
Drugs Aging. 1999 Jul;15(1):69-75; discussion 76. doi: 10.2165/00002512-199915010-00006.
2
Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.
Cancer Chemother Pharmacol. 1981;6(1):25-30. doi: 10.1007/BF00253006.

本文引用的文献

1
Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.
Recent Results Cancer Res. 1981;76:7-15. doi: 10.1007/978-3-642-81565-2_2.
2
Concept of a volume of distribution and possible errors in evaluation of this parameter.分布容积的概念以及该参数评估中可能存在的误差。
J Pharm Sci. 1968 Jan;57(1):128-33. doi: 10.1002/jps.2600570125.
3
Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.将人体视为具有单室性质进行药代动力学分析时存在的缺点。
J Pharm Sci. 1968 Jan;57(1):117-23. doi: 10.1002/jps.2600570123.
4
Distribution of daunomycin and adriamycin in mice. A comparative study.柔红霉素和阿霉素在小鼠体内的分布。一项对比研究。
Biomedicine. 1973 Jul 20;19(7):304-7.
5
Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.
Cancer Res. 1976 Jun;36(6):2108-9.
6
N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.N-三氟乙酰阿霉素-14-戊酸酯,一种比阿霉素具有更强实验性抗肿瘤活性且毒性更小的类似物。
Cancer Res. 1975 May;35(5):1365-8.
7
Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay.采用荧光法和放射免疫分析法测定血浆阿霉素和柔红霉素水平。
Clin Pharmacol Ther. 1977 Jan;21(1):70-7. doi: 10.1002/cpt197721170.
8
Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate.
J Pharmacol Exp Ther. 1978 Mar;204(3):696-701.
9
Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate.
Cancer Treat Rep. 1978 Jan;62(1):111-7.
10
Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.
Cancer Res. 1978 Feb;38(2):365-70.